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Overlap amongst seed clusters that passed initial filtering in 121 head and neck squamous cell carcinomas (HNSCC) (A), 959 breast cancers (BC) (B) and 170 clear cell renal cell carcinomas (CCRCC) (C). Genes within red boxes are those with highly overlapping expression patterns that were then used to generate tumor typespecific angiogenesis meta-signatures. Datasets considered are shown in Table in (A) Expression analysis of the core signature showed significant upregulation in purified breast cancer stroma compared to normal (GSE9014; GEO database), average fold change between tumor stroma and normal tissue was 2.62 (linear scale, 1.39 when logged base2; t-test 2-sided). (B) Expression distribution in the 53 samples, boxplots are provided for each core signature gene in the same dataset used in (A) (relative to normal tissue level). The normalized and annotation datasets were downloaded from GEO, mean expression values were considered across replicate samples. Boxplots in (A) and (B) show the median value, and first and third quartiles. (C) Six genes from the core signature (ELDT1, CD93, GPR116, RGS5, GPR124, EDNRB) and 3 genes (LMO2, DCHS1, FZD4) from the extended common angiogenesis signature were selected and their expression analysed by qPCR in HUVEC stimulated for 16h with 2 different rhDLL4 concentrations. (D) qPCR analysis of a known NOTCH target gene. Bars represent means ±SD (n=6; paired t-test). In renal cancer, EC ELTD1 score has borderline correlation with overall survival but no statistical relevance for relapse free survival (A) while the difference in score between tumor-associated and normal ECs shows borderline statistical correlation with both overall and relapse free survival in renal cancer (B). (C) Representative IHC pictures of ELTD1 score categories (scores 1/2 are taken from normal colon while score 3/4 from colorectal cancer cases). Arrow heads indicate blood vessels. Scale bar: 20μm. (D) Summary of ELTD1 expression in 119 cases of colorectal cancer with normal matched colon. Each column represents a patient with red and white bars showing the score in tumor-associated and normal ECs respectively. (E) Higher tumor endothelial ELTD1 score shows significant correlation with better overall survival in univariate analysis (multivariate analysis not applicable). HR = Hazard Ratio. (F) Endothelial ELTD1 levels positively correlate with MVD in renal, head and neck and colorectal cancer (average MVD ±SD is highlighted). (G) ELTD1 mRNA expression anti-correlates with a hypoxia gene signature and CA9 levels in head and neck cancer. (Figure 7 ): reduced tumor weight (E) and decreased number of nodules (F). Analysis on body weight (G), heart/body weight ratio (H) and heart histology (I) did not show any evidence of adverse effects. Similarly, Eltd1 siRNA (#1)/CH-NP treatment in the HCT116 colorectal s.c. model caused a strong reduction in tumor weight (J), associated to significant Eltd1 silencing (K) and no effect on heart/body weight ratio (L). At the histological level, we observed reduced MVD (CD31 IHC), associated to increased hypoxia (CA9 IF), EC apoptosis (CD31/Tunel IF) and pericyte coverage (CD31/Desmin IF) (M). All these changes are consistent with observations in the ovarian cancer model. All graph bars represent average ±SEM (unpaired t-test). 
Supplemental experimental procedures

Gene expression profiling: datasets, data processing and annotation
Head and neck squamous cell carcinoma (HNSCC) and breast cancer (BC) databases of patients treated in
Oxford were used together with datasets retrieved from the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/). All details are reported in the following Table. The NCBI database was searched for gene expression datasets in HNSCC, BC and clear cell renal cell carcinoma (CCRCC), whose details had been published in peer-reviewed journals, and where microarray analyses were performed on frozen material extracted before patient treatment.
Eleven datasets (see following Table) , encompassing a total of 1250 cases (959 BCs, 121 HNSCCs and 170
CCRCCs), were selected from studies using similar technology platforms (Affymetrix U95, U133 and plus2 arrays) with comparable population demographics per cancer type.
Datasets used for the analysis:
Name Size Tumor type Reference
Vice125 59 HNSCC (Winter et al., 2007) GSE2379 20 HNSCC (Cromer et al., 2004) GSE6791 42 HNSCC (Pyeon et al., 2007) GSE6532Oxf 186 BC (Loi et al., 2008) GSE6532KI 149 BC (Loi et al., 2008) GSE6532GUY 87 BC (Loi et al., 2008) GSE2034 286 BC (Carroll et al., 2006) GSE3494 251 BC (Miller et al., 2005) GSE15641 32 CCRCC (Jones et al., 2005) GSE17816 36 CCRCC (Dalgliesh et al., 2010) GSE17818 102 CCRCC (Dalgliesh et al., 2010) HNSCC, head and neck squamous cell carcinoma; BC, breast cancer; CCRCC, clear cell renal cell carcinoma
Initial processing of gene expression data was performed for all datasets as described in Buffa et al (Buffa et al., 2010 ; specifically, the gcrma function in R was used to estimate expression values, data were quantilenormalized and logged (base2).
Seed clustering
The retrieved microarray datasets were analysed as previously reported in Buffa et al. (BJC; ) (Buffa et al., 2010 , where a similar approach was used to generate a common hypoxia signature. Specifically, multiple prototype genes (or seeds) were selected on the basis of published evidence of involvement in angiogenesis, and/or expression in vessels, with particular attention to genes upregulated in tumor-associated vessels (see following table) . High expression of these genes indicates the presence of a high number of vessels in the specific sample. In this respect, the signature was used as a surrogate marker of MVD to enable identification of a pool of genes possibly involved in the angiogenic process. This is based on the hypothesis that if there is a high MVD there must have been active angiogenesis. These selection criteria were utilized as our aim was to build an angiogenesis profile and study the expression of genes regulated in tumor-associated EC in vivo.
However, not all genes identified are necessarily directly involved in active angiogenesis and thus further validation is paramount in order to validate the involvement of an individual gene in blood vessel formation. A list of all "seed" genes is presented in the following Table. Genes selected as initial "seeds" for the seed clustering. Seeds were tested for expression, variability and ability to form a cluster (see methods); only seeds that passed these initial filtering criteria were used to generate the angiogenesis signature (highlighted with red boxes in Figure S1 for each tumor type). A subset of core seeds showed a similar clustering pattern in all tumor types (in red). To avoid artefacts arising from low expression and small variability, stringent filtering was applied to the initial seeds. Specifically, to be considered in the analysis seeds needed to be expressed with an average expression higher than the 50 th percentile and coefficient of variation greater than 10%, and to be not knowingly affected by cross-hybridization (using Affymetrix annotation data). When multiple probesets matched to the same gene ID, filtering was applied to each of them and correlation between them was estimated. If correlation was significant (Bonferroni adjusted p<0.05), then the median expression of all probesets was considered as the expression of the seed gene; if all-but-one probesets were correlated, the median expression of all correlating probesets was used. Otherwise, the probeset with larger absolute expression range was chosen as representative.
Derivation of cancer type-specific and core angiogenesis signatures
These seeds, or prototypes, were used as a starting point from which to build a co-expression network using seed clustering in a meta-analysis context as described previously (Buffa et al., 2010) . Briefly, in each dataset a connectivity score, C, is estimated for each gene using bootstrapping techniques; C represents the strength of the relationship between each gene and the whole set of seeds. These scores are thus used in a semiparametric meta-analysis across datasets to define a gene meta-connectivity score, Ĉ, for each cancer type.
Finally, a common signature that is shared between tumor types is derived by considering the metaconnectivity scores product. This is effectively a rank product, as Ĉ is an average rank. Genes showing a product >0.25 formed the extended common angiogenesis signature (top-ranked in one cancer type and above-average rank in the others), genes with a product >0.9 formed the core signature (top-ranked in all cancers).
The process defines also a shared neighborhood, S, between seeds; S is the number of genes (corrected by the degree of correlation) shared by the seed clusters. Two seeds are considered to carry a high degree of related information if their clusters share many genes (high S); conversely, seeds that show low S (S<0.5) with all other seeds are filtered out from the seed clustering.
Compactness of the derived meta-signatures is assessed using an iterative hierarchical clustering method with
Bayes information criteria to assess the number of separated clusters (TwoStep clustering, SPSS 15.0). This is an unbiased method to establish numbers of independent clusters 
FANTOM4 project CAGE analysis
Results from the FANTOM4 project (http://fantom.gsc.riken.jp/) were used here as further validation of the genes in the meta-signature. A full description of the CAGE methodology and analysis are available via the FANTOM4 project (http://fantom.gsc.riken.jp/4/download/). Briefly, HUVEC grown over rhDLL4 (1μg/ml) or BSA (control) coated plates for 16h were harvested and RNA was extracted and then used for Cap Analysis Gene Expression (CAGE). The CAGE tags were generated and mapped to the genome and clustered to define transcription start sites (TSS). The TSS have also been mapped to Ensembl transcripts where possible and expression quantified in order to compare the different experimental conditions.
Xenograft tumor models and tissue processing
All protocols were carried out under UK Home Office regulations as previously described (Li et al., 2007) .
Human glioblastoma U87GM cells (10 7 ) were subcutaneously implanted into 7 to 8-week-old female BALB/c SCID mice (Harlan Sprague Dawley, Inc., Indiana), 100μl of cell suspension mixed with an equal volume of matrigel (BD Bioscience). Each group consisted of 5 mice. Tumor growth was measured using a caliper and calculated from the formula: "V = L x W x H x π / 0.52".
Acute drug treatments: when tumors reached the size of 0.35-0.45 cm 3 , the mice were treated by intraperitoneal injection (i.p.) of Bevacizumab (10mg/kg body weight), dibenzazepine (DBZ; Syncom Groningen, The Netherlands) (8.1mmol/kg) (Li et al., 2011) or phosphate buffered saline (PBS) as a control.
After 3 days, a second dose of Bevacizumab or DBZ was given and, 4h later, the mice were sacrificed and the tumors were collected. Half of each tumor sample was freshly frozen in liquid nitrogen and subsequently used for RNA extraction.
Chronic Bevacizumab treatment: Bevacizumab was injected i.p. every three days at a dose of 10mg/kg, starting when the tumor reached 0.15 cm 3 until the end of the experiment. Animals were sacrificed when the tumors reached the maximal allowed size and samples were collected and freshly frozen in liquid nitrogen.
Microarray analysis of gene expression in xenograft samples
Snap-frozen tissues (5 different tumors per treatment type) were crushed to powder in liquid nitrogen by homogenization. Total RNA was extracted using TRI reagent, as per the manufacturer's instruction. Total RNA was cleaned-up by using Qiagen's RNeasy mini kit. The RNA quality was assessed using RNA 6000 Nano Chips Immunohistochemistry and immunofluorescence analysis IHC of primary human tissues: ELTD1 staining was performed using an anti-human ELTD1 antibody (Ab;
HPA025229 from Sigma-Aldrich) recognizing the extracellular domain of the protein. In brief, paraffinembedded slides were de-waxed and antigen retrieved by microwaving in 50mM Tris-2mM EDTA (pH 9.0).
Sections were incubated with the Ab (1:500; about 1μg/ml) at room temperature for 45 minutes. Bound Ab was detected using the Envision system (DAKOCytomation, Ely, Cambridgeshire, UK), visualized by using 2,3-diaminobenzidine chromogen and counterstained with hematoxilin. Matched samples were stained in parallel and tonsil sections were used as controls. Cores were scored for ELTD1 immunolabeling intensity on a semi quantitative scale. The vascular staining correlated with clinico-pathological data was specifically endothelial cell expression, identified histologically as the most adluminal cell in a vessel (vascular smooth muscle cell staining was not scored). Vessels surrounded by tumor were selected for scoring. Negative staining was reported as score 0, scores 1-4 were used for increasing intensity of ELTD1. The highest score among replicates (2 cores for colorectal samples) was considered as representative. In survival analysis, the cut-off score was chosen based on the discrete value more likely to differentiate between normal and tumoral levels.
CD31 staining was performed using an anti-human CD31 antibody (JC70A from DAKO; 1μg/ml; citrate buffer pH 6.0). MVD was then scored by counting the number of CD31 positive vessels per TMA core (only whole cores were scored).
IF of primary human tissues: FFPE tissue sections were de-waxed, antigen-retrieved and permeabilized as already described and co-stained with anti-ELTD1 (1:500) and either anti-CD34 (1:100; QBEnd/10; Novus Biologicals LLC, Littleton, CO, USA) or Cy3-conjugated anti α-smooth muscle actin (α-SMA; 1A4; SigmaAldrich). Secondary fluorescent antibodies were purchased from Invitrogen. Pictures were taken using a wide field digital fluorescence microscope (Zeiss, Germany).
IHC and IF of xenografts: IHC analysis for cell proliferation (Ki67, 1:200, Zymed), microvessel density (MVD, CD31, 1:500, Pharmingen), macrophage number (CD68, 1:400, Serotec) and hypoxia (carbonic anhydrase Anti-CA9, 1:500, Novus), and IF for apoptosis (TUNEL, 1:200, Promega) and pericyte coverage (CD31/desmin, 1:500 and 1:200, Abcam) were all performed as described previously (Lu et al., 2010; Thaker et al., 2006) . For statistical analyses, sections from five randomly selected tumors per group were stained and 5 random fields per tumor were scored. Pictures were taken at x200 or x100 magnification. All stainings were quantified by 2 investigators in a blinded fashion.
In vitro RNA interference and cDNA transfection ELTD1-specific small interfering RNAs (siRNAs) and negative control with similar GC content (medium GC content) were transfected at a final concentration of 20nM using RNAiMAX reagent (all by Invitrogen). siRNA 
RNA extraction, reverse transcription and quantitative PCR
Total RNA from cell cultures was isolated using the RNeasy mini kit (Qiagen, Crawley, West Sussex, UK)
according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized from 0.5-1μg of total RNA using Superscript III first-strand system (Invitrogen). Quantitative PCR (qPCR) analysis was performed in triplicate using the SYBR GreenER qPCR SuperMix Universal (Invitrogen) and Chromo4 fluorescence detector (MJ Research, Waltham, MA, USA). Relative quantification was done using the ΔΔCt method normalizing to β2-microglobulin gene expression. For primer sequences see following 
Western Blotting
Cells were lysed in RIPA buffer and 5-10µg of proteins were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) on 4-12% gradient gels (Invitrogen) and then transferred by conventional semidry blotting. Anti-ELTD1 (1:1000) and anti β-actin (1:20,000) were both from Sigma-Aldrich.
Horseradish peroxidase (HRP)-conjugated secondary Abs were purchased from DAKO and labeling was detected using the enhanced chemiluminescence (ECL) reagent (GE Healthcare, Chalfont St Giles, UK). Nondenaturing conditions were also used according to the blue native gel technique following manufacturer's instructions (Invitrogen).
3D in vitro sprouting angiogenesis assay
HUVEC spheroids of defined cell number (500-1000 cells) were generated by the hanging-drop method (Korff and Augustin, 1998) . Briefly, 4h after siRNA transfection, cells were harvested and re-suspended in culture medium containing 0.20% (wt/vol) carboxymethylcellulose and seeded in non-adherent round-bottom 60-well mini trays (Nunc). 16-24h later, spheroids were collected and embedded into 200μl of matrigel (BD Biosciences). After polymerization, spheroids were cultured for 24h in the presence of EBM2 medium and growth supplements (EGM2 bullet kit, cat. number CC-3162, Lonza). Thereafter, angiogenesis was quantified by counting the number of sprouts for each spheroid and the 20 spheroids with the most sprouts per condition were considered for statistical analysis. Although the standard protocol contains collagen as the extracellular matrix, and VEGF or bFGF as single factors to induce sprouting, matrigel was selected for the reasons described in the adhesion assay (Supplemental Information). In a set of experiments, 4h after transfection cells were prelabeled with viable fluorescent dyes according to manufacturer's protocol (cell tracker green, cat. number C2925, and blue, cat. number C2111; Invitrogen). Spheroids were generated by mixing control and ELTD1 knockdown cells in a 1:1 ratio and both color combinations were analysed. Spheroids were then embedded into 150μl of matrigel and plated on glass-bottom dishes (MatTek, Ashland, MA, USA). After 24h, spheroids were fixed over night at 4 o C in 4% formaldehyde-PBS and pictures of the sprouts were taken using a confocal microscope (Zeiss LSM 510 META). The number of tip and stalk cells of each color were counted.
Adhesion assay
24h after siRNA transfection, 10 x 10 3 cells were seeded on 55µl of matrigel in 96-well plate wells. Cells were left to adhere for 30 minutes before being extensively washed with PBS to remove all not adhering ones. After fixing with 4% formaldehyde-PBS a low magnification picture was taken at the center of each well. Cells number was then quantified by image analysis using Image J software (Image J website, rsbweb.nih.gov). Cell adhesion to matrigel, a complex extracellular matrix produced by tumor cells was studied because the ELTD1 ligand is unknown and we wanted to recapitulate a tumor-like context.
Wound healing assay
After siRNA transfection, cells were allowed to grow until confluent, before a cross ("wound") was made by scraping the cell monolayer with a P200 pipette tip in the center of the well. Pictures of the wound were taken at the four arms of the cross at different time points until complete coverage was achieved. The open wound surface was then quantified by image analysis using Image J software Zebrafish husbandry, eltd1 probe generation and whole mount in situ hybridization
Wild-type (WT) and transgenic Tg(kdrl:GFP) (Beis et al., 2005; Huang et al., 2003) embryos and adult fish were raised and maintained as described (Westerfield, 1993) .
The 700bp eltd1 cDNA was amplifyed from a 27hpf cDNA using the PCR primers 5'-GTTATACATCGCCAGCAGGGCCC-3' and 5'-TCACCCGCTGCTGCATAGCG-3', followed by subcloning into the pGEM-T easy vector (Promega). Antisense mRNA was transcribed from the cDNA template linearized with SacII using SP6 RNA polymerase. Whole mount in situ hybridization on zebrafish embryos was carried out as previously described (Jowett and Yan, 1996) . Antisense RNA probes were transcribed from linearized templates in the presence of digoxigenin (Roche). DIG antibody was detected using BM-Purple (Roche).
Morpholino (MO) injection in zebrafish embryos
MO targeting the pre-mRNA of eltd1 were designed by Genetools: eltd1 ATGMO 5'-CATTGGAGAACTGTGTAAAAACTCC-3' (2.75ng/embryo) and eltd1 spliceMO 5'-ATATATGCCAAACCTCTACAATCGC-3', which targets the exon 2/intron 2 splice-donor site (12ng/embryo). To validate the efficiency of the eltd1 spliceMO, RT-PCR was performed on cDNA collected at 27hpf from WT and eltd1 spliceMO injected embryos, using the following primers: 5'-ACTCCTGCTTTTCGCTGCTTGGT-3' (which binds exon1/2) and 5'-GGTCACATCGTTCAGTGGAAGCGT-3' (which binds exon 9), amplifying a correctly spliced product of 1162bp. Dll4 MO (5'-TGATCTCTGATTGCTTACGTTCTTC-3') was injected at 12ng/embryo (Hogan et al., 2009 ).
Embryo imaging
Images were obtained on a Nikon SMZ 1500 zoom stereomicroscope using a Nikon DXM 1200 digital camera (Nikon, UK). GFP + embryos were visualised using a Leica MZ FLIII fluorescence stereomicroscope (Leica Microsystems, UK) and photographed with a Hamamatsu ORCA-ER camera driven by Simple PCI 5.1.0.0110 (Compix, USA). Confocal images were obtained using a Zeiss LSM 510 META confocal laser microscope, and 3D
projections were generated using Zeiss LSM (Carl Zeiss Inc). Images were processed with Adobe Photoshop CS4
(Adobe Systems, San Jose, CA).
